|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-3-20
|
|
pubmed:abstractText |
Anilinoalkynylpyrimidines were prepared and evaluated as dual EGFR/ErbB2 kinase inhibitors. A preference was found for substituted phenyl and heteroaromatic rings attached to the alkyne. In addition, the presence of a potential hydrogen bond donor appended to this ring was favored. Selected molecules in the series demonstrated some activity against human tumor cell lines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:AlligoodKrystal JKJ,
pubmed-author:BorosEric EEE,
pubmed-author:BouvierFredericF,
pubmed-author:DickersonScott HSH,
pubmed-author:McDonaldOcterloney BOB,
pubmed-author:RastagarAbdullahA,
pubmed-author:ReepBryanB,
pubmed-author:RenoMichael JMJ,
pubmed-author:RudolphSharon KSK,
pubmed-author:RusnakDavid WDW,
pubmed-author:StevensKirk LKL,
pubmed-author:UehlingDavid EDE,
pubmed-author:WatersonAlex GAG,
pubmed-author:WoodEdgar RER,
pubmed-author:ZhangYue-MeiYM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2419-22
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16483772-Alkynes,
pubmed-meshheading:16483772-Cell Line, Tumor,
pubmed-meshheading:16483772-Cell Proliferation,
pubmed-meshheading:16483772-Crystallography, X-Ray,
pubmed-meshheading:16483772-Drug Screening Assays, Antitumor,
pubmed-meshheading:16483772-Humans,
pubmed-meshheading:16483772-Models, Molecular,
pubmed-meshheading:16483772-Molecular Structure,
pubmed-meshheading:16483772-Pyrimidines,
pubmed-meshheading:16483772-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16483772-Receptor, erbB-2,
pubmed-meshheading:16483772-Structure-Activity Relationship
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
|
|
pubmed:affiliation |
GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709-3398, USA. Alex.G.Waterson@gsk.com
|
|
pubmed:publicationType |
Journal Article
|
